Best Myelofibrosis Podcasts (2024)

1
Managing Myelofibrosis with a Patient-Centered Approach

1d ago

—

Guest: Justin Arnall, PharmD, BCOP, CPP Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerry L. Spivak MD, MACP After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to select the best intervention. Having a personalized approach to treatment and management could have a beneficial impact on the ove…

1
Anemia and Myelofibrosis: Optimizing Diagnosis, Treatment, and Management Strategies

4d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, div…

1
Evolving Gene Therapy: A Deep Dive into 3rd-Generation Lentiviral Vectors

2d ago

—

Host: Matt Birnholz, MD Guest: Donald Kohn, MD Third-generation lentiviral vectors were developed to improve upon safety measures and mitigate the risks of toxicity and replication that are typically associated with first- and second-generation therapies. These advancements may help enhance the functionality and utility of third-generation lentivir…

1
Preventing Allergic Reactions to Peanuts with a Cancer Drug

24h ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Melanie Dispenza, MD The future therapeutic landscape for food allergy prevention is looking clearer as a drug typically used to treat hematologic malignancies has shown to prevent systemic anaphylaxis to allergens and increase patients' tolerance to peanuts. Along with this, other therapies are also …

1
Navigating the Crisis: How to Diagnose and Treat Malignant Hyperthermia

17h ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Henry Rosenberg, MD Malignant hyperthermia is an inherited disorder primarily recognized by anesthesia professionals. And since this condition can have significant consequences on a patient’s health, including their likelihood of surviving surgery, it’s important to know how to diagnose and treat mali…

1
Innovations in Adherence: Long-Acting Agents for Infectious Diseases

2d ago

—

Host: Charles Flexner, MD Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner …

1
Anemia and Myelofibrosis: Optimizing Diagnosis, Treatment, and Management Strategies

4d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, div…

1
Exploring the Significant Presence of Anemia in Myelofibrosis

4d ago

—

Host: Jennifer Caudle, DO Guest: Jason Tremblay Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we’re using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremb…

1
Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences 1:35:11

6d ago1:35:11

1:35:11

Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.By Neil Love, MD

1
Increasing CKD Awareness and Early Detection in Adult Patients

9d ago

—

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Christin Iroegbu PhD, RN If left untreated, chronic kidney disease (CKD) can progress to end-stage renal disease, requiring dialysis or kidney transplant as the only treatment options. So communicating this to patients, along with chronic conditions that could contribute to this are key. …

1
Assessing Omalizumab for Food Allergy Treatment

9d ago

—

Host: Jennifer Caudle, DO Guest: Sayantani Sindher, MD Recently, Omalizumab was studied in patients due to the avoidance of management and guidance when it comes to treating food allergies in children and adults. According to this doctor, approximately 45 percent of patients seen in his clinic have multi-food allergies that are not being met with c…

1
Navigating Myelofibrosis Treatment Complexities to Optimize Care

12d ago

—

Host: Jennifer Caudle, DO Guest: Jason Tremblay Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this di…

1
South Asians With IBD: Underrepresented and Underappreciated

10d ago

—

Host: Tauseef Ali, MD, FACG, AGAF Host: Sabina Ali, MD Host: Neil Nandi, MD, FACP Host: Tina Aswani-Omprakash, MPH A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.…

1
Maximizing B-Cell Lymphoma Outcomes with CAR T-Cell Therapy and Personalized Care

15d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tara Graff, DO, MS The therapeutic landscape for relapsed or refractory B-cell lymphoma has greatly evolved in the past several years, with CAR T-cell therapy and personalized care becoming increasingly important in the second-line setting. Joining Dr. Charles Turck to discuss how CAR T-cell therapy a…

1
B-Cell Lymphoma Care: Overcoming Challenges in the Second-Line Setting

15d ago

—

Guest: Matthew Lunning, DO, FACP It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges and unmet needs exist in this setting, which is why Dr. Matthew Lunning is here to discuss those challenges as well as th…

1
Managing B-Cell Lymphomas in the Second-Line Setting: The Role of CAR T-Cell Therapy

19d ago

—

Host: Jennifer Caudle, DO Guest: Sarah Rutherford, MD Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell th…

1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer 48:15

21d ago48:15

48:15

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma 1:00:13

22d ago1:00:13

1:00:13

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.By Neil Love, MD

1
Severe Allergic Reactions: The Potential Detriments of Diphenhydramine

1M ago

—

Guest: Douglas Jones, MD A recent study was done to show the side effects of diphenhydramine for allergic reactions, and one of the main detriments was that it could impair the patient by making them tired or sleepy. Another finding was that it doesn’t work that quickly, so in turn, giving diphenhydramine in a severe allergic reaction could cause m…

1
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer 36:29

1M ago36:29

36:29

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatmen…

1
Improving CKD Patient Outcomes with SGLT2 Inhibitors

1M ago

—

Guest: Gates B. Colbert, MD, FASN A class of medications called SGLT2 inhibitors have been proven to make a major difference for patients with chronic kidney disease (CKD) with and without diabetes when added to angiotensin converting enzyme (ACE) and angiotensin receptor blockers (ARB) classes of medications. Several medications that have been wel…

1
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

1M ago

—

Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.…

1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series 1:00:12

1M ago1:00:12

1:00:12

Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.By Research To Practice

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia 58:01

2M ago58:01

58:01

Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.By Neil Love, MD

1
SUD Among Physicians: The Journey of Seeking Help and Treatments

2M ago

—

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Clinicians experiencing substance abuse disorder (SUD) may have some reluctance about utilizing a Physician Health Program; however, it’s important to know what your resources are in terms of formal treatment and to seek a psychiatrist with addiction specialization. Dive into part two o…

1
Unveiling the Numerous Benefits of RTA Prefilled Syringes

2M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John Hertig PharmD, MS, CPPS Here in the United States, we're investing a little more into cost effectiveness to make the best use of very limited healthcare resources. When ready-to-administer (RTA) syringe products were compared against traditional vial and syringe, there was a significant holistic …

1
Improving CKD Awareness: Emphasizing the Risk in Patients Who Are Unaware

2M ago

—

Host: Ashley Baker, MSN, PMHNP Guest: Chi D. Chu, MD, MAS The National Health and Nutrition Examination Survey found that kidney disease awareness among patients in the U.S. is very low. And alarmingly, the proportion of awareness has not changed much over the 15-year period of this study. To uncover more of the findings and how to improve CKD awar…

1
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib

2M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neeraj Agarwal, MD, FASCO TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a …

1
Uncovering the Prevalence of Mental Health and SUD Among Physicians

2M ago

—

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Along with the general population, physicians are vulnerable to substance use disorder (SUD) with rates as high as 10 to 14 percent. And with demanding careers, stress and burnout can often exacerbate SUD. Tune into part one of this discussion with Dr. Michael Greenberg as he takes a de…

1
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access

2M ago

—

Host: Rishi Sekar, MD A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in…

Podcasts Worth a Listen

Myelofibrosis Podcasts

Podcasts Worth a Listen

Quick Reference Guide